IAP6 Rec'd PCT/PTO 14 APR 2006

## FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 731063000 US Express Mail Label Number

14 April 2006 Date of Deposit

Form PTO-1390-MOD U. S. (REV 10-96)	ATTORNEY'S DOCKET NUMBER 4-33318A								
TRANSMITTAL LETTER TO T DESIGNATED/ELECTED O	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
CONCERNING A FILING UN	10/575814								
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED							
PCT/EP2004/011651	10 October 2004 (10.10.04)	16 October 2003 (16.10.03)							
TITLE OF INVENTION									
DIFFERENTIALLY EXPRESSED GENES RELATED TO CORONARY ARTERY DISEASE									
APPLICANT(S) FOR DO/EO/US									
CHIBOUT ET AL.									
Applicant herewith submits to the United States De	esignated/Elected Office (DO/EO/US) the	ne following items and other information:							

This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5.  $\boxtimes$ a. is transmitted herewith (required only if not transmitted by the International Bureau). c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). a. 

are transmitted herewith (required only if not transmitted by the International Bureau). b. A have been transmitted by the International Bureau. c. In have not been made; however, the time limit for making such amendments has NOT expired. d. A have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. ☐ A SECOND or SUBSEQUENT preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. 16. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).

20. 

Other items or information: Unexecuted Declaration; Application Data Sheet

IAP20 Rec'dPCT/PTO 14 APR 2006

U.S. APPLICATION NO							4-33318A	DOCKET NUMBER				
The following fe										CULATIO	NS PTO USE	
The lonowing rees are submitted.						ONLY						
21. 🛛 Basic national fee												
22. Examination Fee												
☐ If International preliminary examination report was prepared by USPTO												
and all claims satisfy provisions of PCT Article 33(1)-(4)						•						
.  All other situations\$200												
23. Search fee												
If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$												
☑ If International Search Report was prepared and provided to the Office \$400												
L All o	ther situa	ations				• • • • •	•	\$			· ·	
			TOTAL	OF 21, 22 AND 23	3 =				\$	900		
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer												
thereof.			•	The fee is \$250 for		nal 50			fracti	on		
Total Sheets	Extra	a sheets		each additional 50 und up to a whole			RA	TE				
63 - 100 =		/50 =		0		X	\$	250	\$			
Surcharge of \$1	30 for fu	rnichina tha	a noth of dec	claration later than	□ 30				_			
Surcharge of \$130 for furnishing the oath of declaration later than   months from the earliest claimed priority date (37 CFR 1.492(e)).								\$				
CLAIMS		NUMB	ER FILED	NUMBER E	XTRA		RATI			1.050		
Total claims Independent cla	ime	59 9	- 20			X	<u>\$</u>	50 200	\$	1,950 1,200		
MULTIPLE DEF			_			+	\$	360	\$	1,200		
TOTAL OF ABOVE CALCULATIONS =									\$	4,050		
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).							\$					
SUBTOTAL =							\$	4,050				
Processing fee of \$130 for furnishing the English translation later than 30 months from the												
earliest claimed priority date (37 CFR 1.492(f)).							+   EEE	\$	4,050			
TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied							•	4,030				
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +							\$					
TOTAL FEES ENCLOSED =							\$	4,050				
								mount to	\$			
									be:	refunded charged	\$	
a. A check in the amount of \$ to cover the above fees is enclosed.										<b>y</b>		
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$4,050 to cover the above fees. A												
duplicate copy of this form is enclosed.											to	
c.  The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.												
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.												
Send all correspondence to the address associated with Customer No. 001095, which is currently:												
John T. Prince												
Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 43,019						nts						
One Health Plaza, Building 104 (617) 871-3346												
East Hanover, NJ 07936-1080												
April 14, 2006												